Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden).
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy; D003927:Diet, Diabetic; D004341:Drug Evaluation; D005260:Female; D006029:Glycosuria; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011188:Potassium / Q000097:blood; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use; D012964:Sodium / Q000097:blood; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D013548:Sweden; D013997:Time Factors
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D010919:Placebos; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D002784:Cholesterol; D012964:Sodium; D011188:Potassium